J. Haroche, L. Arnaud, and F. Cohen-aubart, Erdheim-Chester disease, Curr Rheumatol Rep, vol.16, issue.4, p.412, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01251639

J. Haroche, F. Cohen-aubart, and B. J. Rollins, Histiocytoses: emerging neoplasia behind inflammation, Lancet Oncol, vol.18, issue.2, pp.113-125, 2017.

E. L. Diamond, L. Dagna, and D. M. Hyman, Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease, Blood, vol.124, issue.4, pp.483-492, 2014.

J. Haroche, C. F. Arnaud, and L. , High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other nonLangerhans cell histiocytoses, Blood, vol.120, issue.13, pp.2700-2703, 2012.

J. F. Emile, O. Abla, and S. Fraitag, Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages, Blood, vol.127, issue.22, pp.2672-2681, 2016.

E. L. Diamond, B. H. Durham, and J. Haroche, Diverse and targetable kinase alterations drive histiocytic neoplasms, Cancer Discov, vol.6, issue.2, pp.154-165, 2016.

G. Cavalli, B. Guglielmi, and A. Berti, The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases, Ann Rheum Dis, vol.72, issue.10, pp.1691-1695, 2013.

L. Arnaud, B. Hervier, and A. Neel, CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients, Blood, vol.117, issue.10, pp.2778-2782, 2011.

G. Goyal, M. V. Shah, and T. G. Call, Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease, JAMA Oncol, vol.3, pp.1253-1256, 2017.

J. Haroche, F. Cohen-aubart, and J. F. Emile, Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease, J Clin Oncol, vol.33, issue.5, pp.411-418, 2015.

J. F. Emile, E. L. Diamond, and Z. Helias-rodzewicz, Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease, Blood, vol.124, pp.3016-3019, 2014.

P. Euskirchen, J. Haroche, and J. F. Emile, Complete remission of critical neurohistiocytosis by vemurafenib, Neurol Neuroimmunol Neuroinflamm, vol.2, issue.2, p.78, 2015.

A. F. Cohen, J. F. Emile, and P. Maksud, Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease, Br J Haematol, vol.180, pp.150-153, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01377866

F. Cohen-aubart, J. F. Emile, and F. Carrat, Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE Study), Blood, vol.130, pp.1377-1380, 2017.

, , p.30, 2017.